Divestment of rights to Covis completed
6 December 2018 07:00 GMT Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma completed AstraZeneca has completed an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna(ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines. The transaction does not include the transfer of any AstraZeneca employees or facilities. Under the terms of